
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District.
The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street's YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and AccreditedEvents.com platforms.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at www.nrxpharma.com.
About New to The Street
New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at www.NewToTheStreet.com.
Media Contact:Monica BrennanPR Coordinator, New to The StreetEmail: Monica@NewToTheStreet.com
SOURCE: New To The Street
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
BrightSpring Health Services Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BrightSpring Health Services (NASDAQ:BTSG) Second Quarter 2025 Results Key Financial Results Revenue: US$3.15b (up 15% from 2Q 2024). Net income: US$9.21m (down 54% from 2Q 2024). Profit margin: 0.3% (down from 0.7% in 2Q 2024). EPS: US$0.046 (down from US$0.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period BrightSpring Health Services Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates by 9.3%. Looking ahead, revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 4.3% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for BrightSpring Health Services (of which 1 is a bit unpleasant!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Universal Display Second Quarter 2025 Earnings: Beats Expectations
Universal Display (NASDAQ:OLED) Second Quarter 2025 Results Key Financial Results Revenue: US$171.8m (up 8.4% from 2Q 2024). Net income: US$67.3m (up 29% from 2Q 2024). Profit margin: 39% (up from 33% in 2Q 2024). The increase in margin was primarily driven by higher revenue. EPS: US$1.41 (up from US$1.10 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Universal Display Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 6.8%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Semiconductor industry in the US. Performance of the American Semiconductor industry. The company's shares are down 2.8% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Universal Display's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Ramaco Resources Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Ramaco Resources (NASDAQ:METC) Second Quarter 2025 Results Key Financial Results Revenue: US$153.0m (down 1.5% from 2Q 2024). Net loss: US$14.0m (down by 381% from US$4.98m profit in 2Q 2024). US$0.26 loss per share (down from US$0.097 profit in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Ramaco Resources Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 47%. Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Metals and Mining industry in the US. Performance of the American Metals and Mining industry. The company's shares are down 16% from a week ago. Risk Analysis Before we wrap up, we've discovered 2 warning signs for Ramaco Resources (1 can't be ignored!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Effettua l'accesso per consultare il tuo portafoglio